Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 24

2405P - Prognostic significance of circulating tumor DNA in patients with urothelial carcinoma: A systematic review and meta-analysis

Date

21 Oct 2023

Session

Poster session 24

Topics

Immunotherapy;  Survivorship;  Cancer Research

Tumour Site

Urothelial Cancer

Presenters

Liu Haoyang

Citation

Annals of Oncology (2023) 34 (suppl_2): S1202-S1228. 10.1016/S0923-7534(23)01271-1

Authors

L. Haoyang1, J. Chen1, Y. Huang2, H. Zeng1

Author affiliations

  • 1 Urology, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 2 Cardiothoracic Surgery, West China Hospital, Sichuan University, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2405P

Background

At present, the prognostic stratification of urothelial carcinoma(UC) patients heavily relies on tumor staging, which is limited by the quality of the tissue samples assessed. Recently, circulating tumor DNA(ctDNA) has shown potential as a molecular tool for the diagnosis, staging, and prognosis of UC. We aimed to conduct a systematic review and meta-analysis to evaluate the prognostic value of ctDNA in patients with UC.

Methods

The MEDLINE, EMBASE, and the Cochrane Library databases were searched from the inception to March 2023 to identify studies investigating the relationship between detection of ctDNA and clinical outcomes in patients with UC. Hazard ratios (HRs) of disease-free survival (DFS) and overall survival (OS) were extracted and meta-analysis was performed using the R software (version 4.2.1).

Results

Twelve studies with 1844 patients were ultimately included in this meta-analysis. Ten studies assessed the relationship between baseline ctDNA detection and patient outcomes. Patients with an elevated ctDNA level exhibited significantly worse DFS (HR=6.22; 95% CI, 3.78-10.25, p<0.001) and OS (HR=4.09; 95% CI, 3.02-7.96, p<0.001). Similar results were observed in subgroup analyses in patients with muscle-invasive UC and metastatic UC, respectively. Four studies evaluated the prognostic value of ctDNA dynamics during treatment or observation. Patients who exhibited a decrease or clearance in ctDNA levels demonstrated a more favorable DFS (HR=0.31, 95% CI, 0.16–0.59, p=0.0003) and OS (HR=0.24, 95% CI, 0.14–0.43,P<0.001) compared to those who did not.

Conclusions

Our meta-analysis demonstrated a robust correlation between levels of plasma ctDNA at baseline/during treatment and oncologic outcomes in patients with UC. These findings indicate that plasma ctDNA offers substantial clinical utility in the risk stratification and personalized prognosis of patients.

Clinical trial identification

The protocol for this review is registered on PROSPERO (CRD42023414380).

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.